NCT07428759

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 50 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.

Conditions

• Pneumonia, Bacterial

Interventions

Type	Name	Description
BIOLOGICAL	Pn-MAPS30plus	Single dose of Pn-MAPS30plus received intramuscularly.
COMBINATION_PRODUCT	PCV20	Single dose of PCV20 received intramuscularly.

Timeline

• Start date: 2026-03-10
• Primary completion: 2026-12-24
• Completion: 2026-12-24
• First posted: 2026-02-24
• Last updated: 2026-04-16

Locations

2 sites across 1 country: Australia